Clinical trials: B-Cell ALL, open to volunteers
Non-small Cell Lung Cancer Stage III, PDL1 Gene Mutation
Study of Antitumor Immune Response After cCRT and IO Treatment in Non-resectable III Stage NSCLC Patients
Observational, multicenter, one-arm, non-comparative study. Data will be recorded in a retrospectively manner. The study will be based on secondary data collected from patient clinical chart completed by the doctor during routine…
- Trial name
- SIENNA (NCT06634199)
- Testing
- Durvalumab
- Where
- 22 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Fundación GECP
B-cell Acute Lymphoblastic Leukemia
A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
This is a multi-center, phase Ib/II trial to evaluate the safety and efficacy of CNCT19 treatment in Children and Adolescent (pediatric) patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).
- Trial name
- NCT05667506
- Testing
- single dose of CNCT19
- Where
- 9 sites in China
- Volunteers
- 47 people
- Sponsor
- Juventas Cell Therapy Ltd.
Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia
Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment
This phase II trial tests how well adding revumenib to usual treatment (blinatumomab) compared to usual treatment alone works in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) or acute leukemia with ambiguous…
- Conditions
- Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia
- Trial name
- NCT07636564
- Testing
- Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration
- Volunteers
- 90 people
- Sponsor
- SWOG Cancer Research Network
Acute Lymphoblastic Leukemia, B-precursor
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
This is a prospective, multicenter, randomized controlled trial designed to evaluate whether short-term blinatumomab intensification before allogeneic hematopoietic stem cell transplantation (allo-HSCT) can improve survival…
- Trial name
- NCT07003737
- Testing
- Blinatumomab, Consolidation Chemotherapy or Direct Allogeneic HSCT
- Where
- China
- Volunteers
- 114 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Relapsed/Refractory B-cell Malignancies
Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies
This is a prospective, single-arm, multi-center, randomized controlled clinical study designed to evaluate the safety and efficacy of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies.
- Trial name
- NCT07345728
- Testing
- Infusion of BAFFR CAR-T therapy for relapsed/refractory B-cell malignancies
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Donghua Zhang
Diffuse Large Cell B-lymphoma
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
The purpose of this study is to assess the preliminary efficacy of TQB2825 in combination with chemotherapy in subjects with diffuse large B-cell lymphoma.
- Trial name
- NCT06854445
- Testing
- TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection
- Where
- 24 sites in China
- Volunteers
- 55 people
- Sponsor
- Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Acute Lymphoblastic Leukemia,B-Cell, Non-hodgkin Lymphoma,B Cell
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for refractory/relapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
- Trial name
- NCT06346912
- Testing
- CD19-BAFF Targeted CAR T-cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang University
Hematologic Malignancy, GvHD
Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
The purpose of this Phase 1, first in human open-label study is to assess the safety and tolerability of TRX-103 in patients with hematological malignancies undergoing HLA-mismatched related or unrelated hematopoietic stem cell…
- Conditions
- Hematologic Malignancy, GvHD, GVHD,Acute, GVHD, Chronic
- Trial name
- NCT06462365
- Testing
- TRX103
- Where
- 5 sites in United States
- Volunteers
- 36 people
- Sponsor
- Tr1X, Inc.
Chronic Lymphocytic Leukemia, Hematopoietic and Lymphoid System Neoplasm
Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT Study
This study evaluates the incidence and management of new and worsening high blood pressure in patients with B-cell cancers on BTKi treatment.
- Conditions
- Chronic Lymphocytic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT06151730
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Relapsing-remitting Multiple Sclerosis
Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies
This prospective, observational clinical study aims to longitudinally assess peripheral immune cell profiles of patients with relapsing-remitting multiple sclerosis (RRMS) receiving anti-CD20 therapy with ofatumumab (OFA)…
- Trial name
- REBELLION-MS (NCT06586177)
- Testing
- Anti-CD20 antibody
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
People who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) are often treated with ibrutinib, acalabrutinib, or zanubrutinib. These are pills that are taken by mouth.
- Trial name
- Benefit VA (NCT06520098)
- Testing
- Venetoclax, Ibrutinib, Acalabrutinib, Zanubrutinib
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- VA Office of Research and Development
Secondary Immune Deficiency
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
This is a prospective, multicenter, open-label, single-arm study to assess the efficacy, safety, and pharmacokinetics (PK) of IgPro20 in adults with hematologic malignancies treated with B-cell targeting Chimeric antigen receptor…
- Trial name
- NCT07648264
- Testing
- IgPro20
- Where
- 60 sites in United States, Belgium and 9 more
- Volunteers
- 63 people
- Sponsor
- CSL Behring
Lymphoma, Lymphoma, B-Cell
A Real-World Study on Extranodal Lymphoma
The aim of this study is to prospectively collect clinical information on patients with extranodal lymphoma, and to explore the best therapeutic strategies in the real-world population.
- Conditions
- Lymphoma, Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Extranodal Lymphoma
- Trial name
- NCT06573099
- Testing
- No interventions need to be specified for this study
- Volunteers
- 5,000 people
- Sponsor
- Ruijin Hospital
B-Cell Lymphoblastic Leukemia/Lymphoma
CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors
This study is a multi-center, open, prospective single-arm clinical study of patients with relapsed / refractory B cell hematological tumors to evaluate the safety and efficacy of CD19 \& CD22 bispecific CAR-T cells in relapsed /…
- Trial name
- NCT06735495
- Testing
- CD19&CD22 bispecific CAR-T cells
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell
Long-term Follow-up Study of Patients Receiving CAR-T Cells
This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital.
- Conditions
- Chronic Lymphocytic Leukemia, Lymphomas Non-Hodgkin's B-Cell, Lymphoma, Small Lymphocytic, Mantle Cell Lymphoma
- Trial name
- NCT03375619
- Testing
- Long-Term Follow-Up of Participants who Received CAR-T cells
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Medical College of Wisconsin
Precursor B-Cell Acute Lymphoblastic Leukemia
Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL
Precursor B cell acute lymphoblastic leukemia (B-ALL) is an aggressive type of leukemia, with high relapse rate and poor long term survival in adults.
- Trial name
- NCT06754267
- Testing
- Venetoclax, Olverembatinib, Predinisone
- Where
- China
- Volunteers
- 36 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Lymphoma, Non-Hodgkin, B-cell Lymphoma
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies.
- Conditions
- Lymphoma, Non-Hodgkin, B-cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular
- Trial name
- BAF_FRontier-1 (NCT07101328)
- Testing
- LY4152199 - IV
- Where
- 51 sites in United States, Australia and 10 more
- Volunteers
- 215 people
- Sponsor
- Eli Lilly and Company
Lupus Nephritis, Membranous Nephropathy
Obinutuzumab for Systemic Lupus Erythematosus Pure Membranous Nephropathy: a Phase II Trial
Lupus nephritis (LN) is a frequent and severe complication of systemic lupus erythematosus, with important mortality and morbidity.
- Trial name
- OBLUMEN (NCT07721363)
- Testing
- Obinutuzumab
- Where
- France
- Volunteers
- 65 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diffuse Large B-Cell Lymphoma
The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
A multicenter, prospective, randomized, open-label, controlled trial to evaluate the efficacy and safety of Pola-ZR2 (polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide) versus ZR2 (zanubrutinib, rituximab and…
- Trial name
- NCT06522555
- Testing
- polatuzumab vedotin, zanubrutinib, rituximab and lenalidomide, zanubrutinib, rituximab and lenalidomide
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ruijin Hospital
Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity
The CARDIOPROTECT Trial
This trial is to evaluate if dexrazoxane is safer and more effective than liposomal doxorubicin in preventing heart failure events in participants with diffuse large B-cell lymphoma (DLBCL) undergoing either standard of care…
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
- Trial name
- NCT07654426
- Testing
- Dexrazoxane, Doxorubicin, Liposomal Doxorubicin
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Beth Israel Deaconess Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.